CINECA IRIS Institutional Research Information System

TRUSOLINO, Livio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.312
AS - Asia 10.157
EU - Europa 10.112
OC - Oceania 272
SA - Sud America 222
AF - Africa 80
Continente sconosciuto - Info sul continente non disponibili 16
Totale 35.171
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.851
CN - Cina 6.073
IT - Italia 2.731
GB - Regno Unito 1.238
DE - Germania 1.202
JP - Giappone 1.066
FR - Francia 795
IE - Irlanda 674
SG - Singapore 671
SE - Svezia 538
ES - Italia 491
FI - Finlandia 475
KR - Corea 473
IN - India 433
HK - Hong Kong 411
CA - Canada 381
NL - Olanda 287
UA - Ucraina 259
PL - Polonia 217
AU - Australia 208
CH - Svizzera 208
TW - Taiwan 201
BE - Belgio 196
BR - Brasile 148
TR - Turchia 147
AT - Austria 144
ID - Indonesia 128
VN - Vietnam 123
RU - Federazione Russa 98
IL - Israele 92
GR - Grecia 91
TH - Thailandia 81
PT - Portogallo 76
DK - Danimarca 72
CZ - Repubblica Ceca 68
MX - Messico 67
NZ - Nuova Zelanda 64
RO - Romania 59
IR - Iran 55
NO - Norvegia 49
HU - Ungheria 35
SA - Arabia Saudita 31
PK - Pakistan 29
MY - Malesia 27
CO - Colombia 23
EG - Egitto 23
CL - Cile 19
AR - Argentina 17
ZA - Sudafrica 16
HR - Croazia 14
LB - Libano 14
SK - Slovacchia (Repubblica Slovacca) 14
MO - Macao, regione amministrativa speciale della Cina 13
UZ - Uzbekistan 13
JO - Giordania 12
NG - Nigeria 12
PH - Filippine 12
QA - Qatar 11
AM - Armenia 10
RS - Serbia 10
SI - Slovenia 10
EE - Estonia 9
LT - Lituania 9
PE - Perù 9
SN - Senegal 9
LU - Lussemburgo 8
AP - ???statistics.table.value.countryCode.AP??? 7
EU - Europa 7
KE - Kenya 7
BA - Bosnia-Erzegovina 6
AE - Emirati Arabi Uniti 5
CY - Cipro 5
EC - Ecuador 5
IS - Islanda 5
KZ - Kazakistan 5
TN - Tunisia 5
BG - Bulgaria 4
BY - Bielorussia 4
CU - Cuba 4
GE - Georgia 4
LK - Sri Lanka 4
OM - Oman 4
PR - Porto Rico 4
IM - Isola di Man 3
KH - Cambogia 3
MK - Macedonia 3
MT - Malta 3
A1 - Anonimo 2
AD - Andorra 2
AL - Albania 2
DM - Dominica 2
DZ - Algeria 2
MA - Marocco 2
PA - Panama 2
BN - Brunei Darussalam 1
GH - Ghana 1
GL - Groenlandia 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
Totale 35.167
Salva come PNG Salva come JPEG
Città #
Beijing 1.330
Chandler 1.118
Ann Arbor 1.049
Shanghai 925
Fairfield 843
Houston 665
Dublin 627
Redwood City 556
Ashburn 496
Singapore 451
Guangzhou 438
Seattle 431
Cambridge 411
Woodbridge 408
Wilmington 402
Torino 380
Tokyo 315
Nanjing 262
Milan 244
Dearborn 240
Turin 222
New York 214
Jacksonville 200
Nyköping 193
Villeurbanne 193
Princeton 188
Hangzhou 186
Wuhan 167
Medford 166
Pisa 162
Boston 161
Warsaw 147
Lappeenranta 146
San Diego 144
London 139
Los Angeles 125
Chengdu 120
Taipei 120
Rome 113
Zhengzhou 111
Vienna 110
Jakarta 108
Fremont 106
Paris 97
Changsha 90
Duncan 87
Boardman 86
Toronto 86
Central 85
San Francisco 84
Munich 83
Brussels 78
Seoul 76
Chicago 75
Dong Ket 75
Ottawa 75
Barcelona 73
Central District 70
Madrid 68
Shenyang 67
Amsterdam 66
Jinan 66
Berlin 65
Naples 65
Chongqing 62
Manchester 62
Helsinki 61
Tianjin 61
Nanchang 60
Santa Clara 60
Norwalk 58
Genoa 51
Fuzhou 49
Hong Kong 48
Hefei 46
Shenzhen 45
Sydney 42
Heidelberg 41
Philadelphia 41
Carrara 40
Xian 40
Bangkok 39
San Jose 39
Osaka 37
Mumbai 36
Dallas 34
Istanbul 34
Phoenix 34
São Paulo 34
Bengaluru 33
Melbourne 33
Pittsburgh 33
Toulouse 33
Vancouver 33
Washington 33
Atlanta 32
Florence 32
Nashville 32
Silver Spring 32
Rochester 30
Totale 18.259
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 5.107
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. 5.093
Stromal contribution to the colorectal cancer transcriptome. 1.864
Adaptive mutability of colorectal cancers in response to targeted therapies 1.750
MET signalling: principles and functions in development, organ regeneration and cancer. 1.548
Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy 1.540
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.148
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 713
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 655
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 637
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 564
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. 344
The genomic landscape of response to EGFR blockade in colorectal cancer 339
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer 329
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 326
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 316
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 311
Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer 298
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 271
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 253
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 247
Only a subset of Met-activated pathways are required to sustain oncogene addiction 245
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment 241
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 241
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype 234
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 232
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 213
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 211
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis 209
Inhibition of Src impairs the growth of met-addicted gastric tumors. 209
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells 202
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 202
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 181
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 179
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 175
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 175
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 172
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors 166
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 166
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga 160
Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody 159
NOTCH3 SIGNALING REGULATES MUSASHI-1 EXPRESSION IN METASTATIC COLORECTAL CANCER CELLS. 157
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils 156
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells 156
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy 156
Inhibition of polyADP-ribosylation in cancer: Old and new paradigms revisited. 152
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 151
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 150
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 145
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 145
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis 143
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 141
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 140
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. 133
PDX-MI: Minimal information for patient-derived tumor xenograft models 131
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 130
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 118
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 118
The heme biosynthesis-heme export axis is required for the modulation of the tricarboxylic acid cycle 117
Effective drug combinations in breast, colon and pancreatic cancer cells 116
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas 109
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer 106
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases 105
Differential integrin expression in thyroid and laryngeal carcinomas. 102
Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma 98
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. 98
The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation 95
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 94
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. 91
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER. 89
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity 87
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 85
Implementing systems modelling and molecular imaging to predict the efficacy of BCL-2 inhibition in colorectal cancer patient-derived xenograft models 82
A membrane glycoprotein identified by the monoclonal antibody BD31 is a component of cell-cell junctions of normal and transformed epithelia. Eur J Cell Biol, 55 (Suppl 35): 54, 1991 80
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective 79
A monoclonal antibody identifies a novel GPI-anchored glycoprotein involved in epithelial intercellular adhesion. 78
Interactions between scatter factors and their receptors: hints for therapeutic applications 76
beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. 76
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle 76
Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue 75
Metabolic adaptation in colorectal cancer: heme export is required for the modulation of the tricarboxylic acid cycle. 75
Altered expression of alpha 6 integrin subunit in oral squamous cell carcinoma and oral potentially malignant lesions. 74
Adhesion molecules in squamous cell carcinoma of the larynx: possible indication of prognosis 74
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. 74
A novel GPI-anchored glycoprotein shows properties of a COOH-terminus truncated cadherin involved in cell-cell contacts of cultured human epithelial cells. 74
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle. 74
Met as a potential therapeutic target in basal-like breast cancer 72
Adhesion molecules in the control of cell proliferation and cell motility. 71
Animal research: Temper Italy's strict lab-animal law. 71
Negative feedback regulation of Met-dependent invasive growth by Notch 71
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. 70
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition 69
Derivation and charaterization of cancer initialling cells representative of metastatic colorectal cancer genetic heterogeneity 69
Adhesion properties and integrin expression of cultured human osteoclast-like cells 68
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin 66
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation 64
Scatter-factor and semaphorin receptors: cell signalling for invasive growth 63
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways 63
Drug development of met inhibitors: targeting oncogene addiction and expedience 62
Innovations, challenges, and minimal information for standardization of humanized mice 62
Totale 33.447
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.210
article - articoli 0
book - libri 0
conference - conferenze 7.240
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.450
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.472 0 0 0 516 304 551 448 335 401 383 290 244
2020/20215.971 279 350 552 552 531 495 639 385 540 557 492 599
2021/20226.037 539 543 490 567 459 423 482 453 457 331 673 620
2022/20235.297 463 424 302 504 415 805 407 467 546 243 365 356
2023/20245.578 466 504 352 487 403 494 450 457 167 562 667 569
2024/20251.773 399 546 574 254 0 0 0 0 0 0 0 0
Totale 35.957